Background. The recent isolation of Brucella microti from the common vole, the red fox, and the soil raises the possibility of an eventual reemergence of brucellosis in Europe. In this work, the pathogenic potential of this new Brucella species in both in vitro and in vivo models of infection was analyzed.
pathogens that are most often associated with brucellosis are Brucella melitensis, Brucella suis, and Brucella abortus. Five other species are less frequently or never responsible for human brucellosis: Brucella ovis, Brucella canis, Brucella neotomae, Brucella ceti, and Brucella pinnipedialis. Recently, a ninth species has been added to this genus, Brucella microti, which was isolated in the Czech Republic from the common vole, Microtus arvalis, a small rodent widespread in Eurasia [2, 3] . B. microti had been first misidentified as Ochrobactrum intermedium, an opportunistic pathogen that is phylogenetically closely related to the Brucella species [2] . Lately, B. microti has been isolated from soil samples [4] and from red foxes [5] . To date, however, the potential pathogenicity of B. microti for livestock and humans remains unknown.
The key aspect of Brucella virulence is its capacity to replicate inside the macrophage host cell and to escape from the host immune system. Indeed, experimental in vitro infection of macrophages by Brucella species has been considered a good model of the interaction between the pathogen and the host cell [6] . A murine model of infection by Brucella species is well established; despite the absence of typical symptoms of brucellosis or death, replication of brucellae in the spleen and liver, as well as chronic infection, has been documented [7] [8] [9] [10] [11] . In this context, it is worth mentioning that experiments with small numbers of ICR (Institute for Cancer Research) mice that were infected subcutaneously with B. microti yielded a mortality rate of 50% [2] .
The aim of this work was to analyze the virulence of B. microti in human and murine macrophages and macrophagelike cells, and its pathogenic potential in in vivo models of murine infection. The behavior of B. microti in vitro was also compared with that of the closely related and well-characterized pathogenic species B. suis.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The strains used in this study were B. microti CCM 4915 and B. suis 1330 ATCC 23444. All strains were grown to stationary phase in tryptic soy broth (Difco), with shaking, at 37ЊC. Resistance of Brucella strains to an acidic environment was evaluated by incubation of bacteria from a stationary culture in minimal medium at pH 4.5 for 7 h [12] . The number of living bacteria in a sample was determined by counting of colony-forming units (CFU) after plating serial dilutions onto tryptic soy agar plates. The smooth phenotype of the strains was verified by crystal violet staining.
Macrophage infections. Infection experiments with macrophage-like murine J774 cells and human THP1 cells and with human monocytes isolated from blood of donors were performed as described elsewhere [13, 14] ; the cells were inoculated with early stationary-phase bacteria at a multiplicity of infection of 20 (J774 and THP1) or 30 (human monocytes), respectively. All experiments were performed 3 times in triplicate.
Murine infection experiments. Established and approved animal-experimentation guidelines were followed for mouse experiments. All animals were females and were purchased from Charles River Laboratories (France).
Time course of infection. In a preliminary experiment, 10 5 CFU of B. microti were injected intraperitoneally into 33 Balb/ c mice that were 8-9 weeks olds. In a second set of experiments, 10 4 CFU of B. microti or B. suis were injected intraperitoneally into groups of Balb/c, CD-1, and C57BL/6 mice (5-6 mice per group). At different time points, blood, spleens, and livers were collected aseptically from mice after euthanasia by CO 2 asphyxiation. Spleens and livers were weighed, homogenized, serially diluted, and plated onto tryptic soy agar for counting of viable Brucella organisms [15] . The bacteria level was determined by plating serial dilutions of whole blood treated with EDTA (ethylenediaminetetraacetic acid). (Table 1) . Eventual death of reinfected animals was recorded over 7 days. Groups of animals were killed at 3 and 7 days, and their spleens were removed to determine bacterial counts.
Statistical methods. The significance of differences between groups in time course and dose response experiments was analyzed by the Student t test. In protection experiments, an analysis of variance using the Fisher protected least-significant-difference test was performed to determine differences between means. Percentages were compared by using the Fisher exact test. P values of р.05 were considered significant. For residual virulence experiments, the RT50 values and their corresponding confidence limits were calculated using the PROC-PROBIT software package (SAS) [16, 17] . Differences between RT50 values were obtained by comparison of regression lines using the same statistical package [16, 17] . 
RESULTS
Enhanced growth in broth and increased acid resistance of B. microti. In tryptic soy broth, B. microti grew significantly faster than B. suis; the generation time was 2 h for B. microti, compared with 3 h for B. suis. On tryptic soy agar, B. microti colonies appeared in 2 days, compared with 3 days for B. suis colonies. In addition, B. microti was more resistant than the B. suis 1330 strain to acid pH in vitro: after 7 h of incubation in minimal medium at pH 4.5, the viability of B. microti was 25% of the input viability, compared with 0.9% for that of B. suis.
Increased replication of B. microti in human and murine macrophages. The virulence of brucellae in a given host species correlates with their ability to replicate inside macrophages. The behavior of B. microti was therefore compared to that of the most closely related species, B. suis, a human pathogen.
This work provides the first evidence, to our knowledge, that B. microti readily multiplies inside human macrophage-like THP-1 cells ( Figure 1A ). There were significant differences between B. microti and B. suis in terms of their ability to replicate in macrophages. At 24 h after infection, the number of intracellular B. microti was ∼100 times higher than that of B. suis (Student t test;
). P р .01 Similar results were obtained in 2 other models of macrophage infection: in human monocyte-derived macrophages ( Figure 1B ) and in murine macrophage-like J774 cells ( Figure  1C) . In both cases, B. microti multiplied at a higher rate than did B. suis over a period of 24 h. In all cell types studied, B. microti was characterized by a significantly lower mortality rate at 7 h after infection (
). This observation correlated with P р .01 the increased growth rate of B. microti in tryptic soy medium and with its resistance to an acidified environment.
Death of Balb/c and CD1 mice at standard doses of infection by B. microti. The susceptibilities of mice to B. microti infection were analyzed and compared following injection of serial doses of bacteria. The symptoms of infected mice were stiff fur, hyperthermia, limping, anorexia, and swelling of the spleen and the liver. In a preliminary experiment, the intraperitoneal injection of 10 5 CFU of B. microti-corresponding to the bacterial dose used in standard murine infections by B. suis [11, 18] -resulted in the death of 27 (82%) of 33 Balb/c mice within 4-7 days after infection. In CD1 and C57BL/6 mice, a similar mortality was obtained after injection of 10 6 CFU, suggesting that CD1 and C57BL/6 mice were more resistant to this species than were Balb/c mice.
To define sublethal doses in the perspective of following up the time course of infection by B. microti, 2 lower doses of bacteria were injected into Balb/c mice: injection of 10 3 and 10 4 CFU resulted in the survival of 100% of the infected mice.
Intrasplenic counts of B. microti were significantly higher at 3 days than at 7 days after injection ( for 10 3 CFU, and P ! .001 for 10 4 CFU), indicating a rapid clearing of infection P ! .001 with sublethal doses of bacteria (Figure 2A) . The decrease of the number of intrasplenic B. microti was associated with an increase of the spleen weight at 7 days after infection, suggesting the onset of a host immune response ( Figure 2B ).
Follow-up of infection caused by sublethal doses of B. microti. The previous observation, which indicated an early peak of infection by B. microti ∼3 days after injection, resulted in a series of infections of Balb/c and CD1 mice at infective doses 100-fold lower than the lethal doses (ie, CFU for Balb/c mice and 10 4 CFU for CD1 mice), followed by killing at 2, 3, and 4 days after injection. For both Balb/c and CD1 mice, the peak of infection was indeed detected at day 2 in the blood ( Figure 3A ) and at day 3 in the spleen and liver ( Figure  3B and 3C) , indicating final accumulation of B. microti-carrying circulating cells of the immune system in these organs. Over the short period of the experiments, increases in spleen and liver weight were more noticeable in CD1 mice, which received a higher dose than did Balb/c mice, thus indicating the onset of an immune response ( Figure 3D and 3E ).
An independent set of infection experiments with a nonlethal infective dose of 10 4 CFU was performed over a period of 28 days, to analyze the fate of B. microti in different murine models of infection in comparison to B. suis. The 3 well-characterized mouse strains Balb/c, CD1, and C57BL/6 were used for Brucella infection. These strains have been validated as appropriate in vivo infection models by many previous Brucella research groups [7, 8, 19, 20] .
At 3 days after injection, Balb/c mice infected with B. microti were characterized by a higher concentration of bacteria in the blood than those infected with B. suis ( ) ( Figure 4A ). P ! .01 However, the number of circulating B. microti dropped significantly faster than that of B. suis: whereas B. microti could not be detected in any of the 3 mice strains starting from days 7 to 14, circulating B. suis disappeared from the blood of CD1 mice between days 21 and 28 after infection, and their number remained constant over the duration of the experiment in Balb/ c mice. For B. microti-infected C57BL/6 mice, enumeration of live bacteria in blood, spleen, and liver yielded similar results to those obtained for CD1 mice. In the spleen and liver target organs, the numbers of B. microti decreased rapidly over a period of 14 days (in CD1 and C57BL/6 mice) or 21 days (in Balb/c mice), after an initial peak of infection at day 3 ( Figure  3B and 3C; Figure 4B and 4C). As described earlier [15, 18] , B. suis-infected Balb/c mice behaved differently: the infection peak was reached at 7-8 days, and decrease in the number of bacteria in the tissues was slow, with persistence observed at least until the end of the experiment at day 28 ( Figure 4B and  4C) . In CD1 mice, B. suis persisted over the period of 28 days, without, however, showing the peak of replication characteristic of infected Balb/c mice. This is consistent with the CD1 phenotype, which is described as more resistant to Brucella infections than is the Balb/c phenotype [19] . As expected, this more resistant host phenotype was also observed in B. microti-infected CD1 and C57BL/6 mice, which eliminated the bacteria more rapidly than did Balb/c mice ( Figure 4B and 4C ). An increase in spleen and liver weights followed by a plateau phase over the first 7-14 days of infection of CD1 and Balb/c mice by B. microti correlated with the decrease of the pathogen in the target organs. The shift of the peak of infection for B. suis correlated with a shift in spleen weight increase, reaching a maximum at 2-3 weeks (Table 2) .
Lower residual virulence in B. microti than in B. suis. Table 1 ). The protective capacity of various infective doses of B. microti was also evaluated at 3 or at 7 days after a challenge with sublethal or lethal doses of the same strain (Table 1) . As early as 3 days after challenge, the B. microti load in murine spleens was 10 4 -fold to 10 7 -fold lower in test groups than in control groups, showing the high degree of protection against reinfection (Table 3) .
DISCUSSION
B. microti is a recently described Brucella species originally isolated from systemically infected common voles (Microtus arvalis) captured in the Czech Republic in 2000 [2, 3] . To date, the potential pathogenicity of this Brucella species for livestock and humans is completely unknown. In this work, the experimental pathogenicity of B. microti has been studied by the infection of macrophage-like cells in vitro and of 3 different strains of laboratory mice. The results presented here demonstrated for the first time that B. microti multiplied in human monocytes and in human and murine macrophage-like cells. The rate of replication of B. microti in the 3 different cellular models of infection was increased, compared with that of B. suis. This result correlated with the higher resistance of the B. microti CCM 4915 strain to acid pH and with its higher rate of replication in broth, compared with the B. suis 1330 strain used in our experiments. The causes of the faster growth rate of B. microti in broth and inside macrophages remain to be determined, but it may be speculated that either the existence of specific metabolic pathways or modulation of protein biosynthesis could participate in the phenomenon. The higher resistance of B. microti to acid pH under low nutrient conditions, to which B. suis is exposed in the early phase of macrophage infection [21, 22] , is a plausible explanation for the observed lack of drop in survival during the first 7 h after infection. Additional experiments will show whether acid pH may nevertheless be a trigger essential for intracellular B. microti replication.
In Balb/c and CD1 mice (the latter are isogenic to the previously described ICR mice [2] ), a standard protocol of infection for brucellae, using 10 5 CFU per injection, resulted in a death rate of 82% within 7 days with B. microti. Prior to death, high titers of bacteria could be found in the blood, liver, and spleen (data not shown), and all infected animals were characterized by severe symptoms described above. This is, to our knowledge, the first report that a species of Brucella has the capacity to kill a wild-type murine host within a few days under standard infection conditions (intraperitoneal injection of 10 5 CFU of bacteria). Second, at the respective peaks of infection, the proportion of bacteria in the blood was higher in B. microtiinfected than in B. suis-infected Balb/c mice, indicating a higher rate of bacterial relocalization toward target organs for the latter. The third observation is that the peak of infection in the organs was reached 4 days earlier with B. microti than with B. suis. This may be linked directly to the higher growth rate of the new species, atypical for brucellae, and which could be one possible explanation for the rapid death of the large majority of the infected mice. At least 2 other hypotheses can be discussed: specific, yet unknown virulence factors, and a lipopolysaccharide-induced septic shock syndrome. This syndrome can be triggered by intraperitoneal injection of Escherichia colilipopolysaccharide into Balb/c mice, resulting in death within 60 h [23] . The lipopolysaccharide from the previously studied species of Brucella, however, is of low endotoxic activity [24] , and Ochrobactrum lipopolysaccharide is similar to Brucella lipopolysaccharide [25] , making this hypothesis less likely. The second phase of mouse infection by B. microti was characterized by a rapid decline of the number of bacteria in spleen and liver, in contrast to B. suis infection. Long-term survival of brucellae in mice toward a chronic state of infection has been described for B. abortus and B. melitensis [7, 8] . The rapid decline of B. microti may be attributed to a stronger innate immune response of the animal or to a higher sensitivity of the pathogen to the host defense reactions. The higher degree of resistance of CD1 and C57BL/6 mice was in agreement with results described elsewhere [8, 19, 26] .
Finally, sublethal doses of B. microti (10 4 CFU for Balb/c mice and 10 5 CFU for CD1 and C57BL/6 mice) induced total protection against subsequent lethal (10 5 CFU for Balb/c mice and 10 6 CFU for CD1 and C57BL/6 mice) or sublethal infective doses of this pathogen, suggesting that rodent populations naturally infected by B. microti may become fully protected after a first exposure to the agent.
In conclusion, our results show that the behavior of B. microti in mice was atypical compared with that of well-known Brucella species and that this new species induced severe pathology and death. In the absence of reported clinical and veterinary cases of infection, and despite its high rate of replication in human macrophages and severity of infection in mice, the pathogenicity of B. microti for humans and domestic animals has not been confirmed yet. The potential risk of the emergence of B. microti as a pathogen in humans and in agriculture is linked to its wildlife reservoirs, with increased risk of direct or indirect transmission to man. Because the common vole is a major food source for a considerable number of predators (including owls, foxes, and boars), it may play a key role in the spread of this bacterium. In addition, this mammal has been described as a zoonotic reservoir for other bacterial and viral pathogens [4, 27] . Because the soil is also a possible habitat of B. microti, other reservoirs, such as nematodes, may exist [4] .
Additional work will be necessary to identify the natural reservoirs and modes of transmission of B. microti, and to investigate its possible pathogenicity in animals raised in agriculture. The biological activity of key virulence factors of Brucella species, such as VirB, will have to be investigated, as well as the factors involved in the increased growth rate and in the death of infected mice. Indeed, recent genome analysis of B. microti led to the hypothesis that this difference in growth rate might be attributed to a change in the 23S ribosomal RNA structure [28] . It is tempting to speculate that this rapid growth rate by itself may be responsible for the mortality of the host during infection with bacterial doses that are not lethal when using other slow-growing Brucella strains. The study of the host immune response to B. microti infection will contribute to a better understanding of the 2 major aspects of this infection in Balb/c mice when standard doses of bacteria are injected: the high degree of host mortality within the first days of infection, followed by rapid clearing of the bacteria from the surviving mice. Human monocellular and multicellular in vitro models will allow the first conclusions to be drawn regarding the immune response to B. microti in humans.
